



Patient **access to biosimilar anti-TNF** has expanded by **+15%** in Denmark (2020)



**+25,000** more UK patients with mild Rheumatoid arthritis get **access to biologic therapy** thanks to biosimilar competition



Since biosimilar medicines have been available, healthcare systems were able to reinvest over **€30BN total savings** across Europe (2022)



A growing opportunity for patients with over **100 new biologic medicines** opening to biosimilar competition by 2030




A considerable opportunity for European healthcare budget: a **\$40BN** market will **open to competition** between 2024-2029



Biosimilars available for cancer treatment have the potential to **reduce treatment costs by €2.4BN** each year in Europe



Biosimilar medicines opportunity remains largely untapped with only **14% volume share** of the accessible market in Europe



Europe remains the global leader with over **50%** of the **biosimilar utilisation**